Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology...(s regarding the future of MEPACT; any st...),Health

Date:5/18/2009

s regarding the future of MEPACT; any statements of the plans, strategies and objectives of management for future operations; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to Takeda's ability to successfully incorporate IDM Pharma's assets into its business operations, the ability to complete post-approval development commitments for MEPACT and the contribution of MEPACT to Takeda's European oncology franchise. These and other risks and uncertainties are discussed in documents filed with the U.S. Securities and Exchange Commission by IDM Pharma, and will be discussed in the tender offer documents to be filed by Takeda or its affiliate and the Solicitation/Recommendation Statement to be filed by IDM Pharma. All forward-looking statements are based on information currently available to Takeda and IDM Pharma, and neither Takeda nor IDM Pharma assumes any obligation to update any such forward-looking statements or other statements included in this press release.

Important Additional Information Will Be Filed with the Securities Exchange Commission (SEC)

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of IDM Pharma, Inc. Takeda America has not commenced the tender offer for shares of IDM Pharma stock described in this press release.

At the time the tender offer is commenced, Takeda America and one of its affiliates will file with the SEC a Tender Offer Statement on Schedule TO and related exhibits, including an Offer to Purchase, Letter of Transmittal and other related documents, and IDM Pharma will file with the SEC a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 in connection with the transaction. These will contain important information about Takeda, Takeda America and IDM Pharma, the
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; IDM Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Takeda to Create Global Centers of Excellence
2. Takeda Receives New Information on Alogliptin (SYR-322) NDA
3. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
4. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
5. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
6. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. Takeda Completes Acquisition of Millennium
9. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
10. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
11. Takeda Announces New U.S. Leadership